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Abstract 
 
Before the introduction of new drugs, we designed a trial where treatment of newly diagnosed myeloma 
patients was based on the presence or absence of HLA-identical siblings. First-line treatments included a 
cytoreductive autograft followed by a nonmyeloablative allograft or a second melphalan-based autograft. 
Here, we report long-term clinical outcomes and discuss them in the light of the recent remarkable 
advancements in the treatment of myeloma. After a median follow-up of 7 years, median overall survival 
(OS) was not reached (P = .001) and event-free survival (EFS) was 2.8 years (P = .005) for 80 patients with 
HLA-identical siblings and 4.25 and 2.4 years for 82 without, respectively. Median OS was not reached (P = 
.02) and EFS was 39 months (P = .02) in the 58 patients who received a nonmyeloablative allograft whereas 
OS was 5.3 years and EFS 33 months in the 46 who received 2 high-dose melphalan autografts. Among 
patients who reached complete remission in these 2 cohorts, 53% and 19% are in continuous complete 
remission. Among relapsed patients rescued with “new drugs,” median OS from the start of salvage therapy 
was not reached and was 1.7 (P = .01) years, respectively. Allografting conferred a long-term survival and 
disease-free advantage over standard autografting in this comparative study. 
Introduction 
 
Autologous transplantation has been regarded as the standard of care for young myeloma patients.1 
Recently, “new drugs” such as lenalidomide and bortezomib have prolonged survival.2,3 Allografting has 
been considered the only potential cure.4 However, the high transplant-related mortality (TRM) has limited 
its use.5,6 After the observation that donor engraftment could be obtained after reduced-intensity purine 
analog-based or nonmyeloablative low-dose total body irradiation (TBI)–based conditionings, allografting 
has become more feasible with acceptable toxicity.7–9 Combining an autograft with a nonmyeloablative 
conditioning and an allograft has lowered TRM to approximately 15% in myeloma.10,11 However, role and 
timing of allografting remain to be determined and convincing evidence that an allograft should routinely 
be performed is lacking. 
 
We report the long-term results of a trial, designed before the introduction of “new drugs,” where the 
treatment assignment of newly diagnosed patients under the age of 66 was based on the presence or 
absence of an HLA-identical sibling (ClinicalTrials. gov number, NCT00415987).12 
  
Methods 
Patients and treatments 
 
A total of 245 patients were consecutively diagnosed with stage IIA-IIIB myeloma from September 1998 to 
July 2004 at 5 Italian centers: San Giovanni Battista Hospital, Tosine; University of Udine, Udine; Santa 
Croce e Carle Hospital, Cuneo; Sant Antonio e Biagio Hospital, Alessandrio; IRCC, Candiole. Of 199 patients, 
166 with at least 1 sibling were HLA-typed to search for a potential sibling donor. Written informed consent 
was obtained from all patients. The study was approved by the 5 Institutional Review Boards according to 
the Declaration of Helsinki. A first report of this trial was previously published.12 
 
Patients eligible for chemotherapy received 2-3 courses of vincristine, adriamycin, and dexamethasone 
(VAD)–based regimens. G-CSF–mobilized peripheral blood stem cells (PBSCs) were collected after 
cyclophosphamide. Patients with HLA-identical siblings were offered the preceding induction followed by a 
standard autograft after melphalan, 200 mg/m2, and, 2-4 months later, by an allograft with PBSCs after 
nonmyeloablative TBI (200 cGy). No maintenance/consolidation therapies were allowed. Patients without 
HLA-identical siblings were assigned to double autologous transplantation after intermediate-dose (100 
mg/m2) or high-dose (140-200 mg/m2) melphalan (Figure 1). 
  
Clinical outcomes were compared between patients with and without HLA-identical siblings and between 
the 2 patient cohorts who received the allograft and the 2 high-dose melphalan autografts.12 
Response criteria 
 
Complete remission (CR) required undetectable serum monoclonal Igs or urine light chains by 
electrophoresis and no monoclonal bands on immunofixation; < 1% marrow plasma cells, and no increase 
in size or number of osteolytic lesions. Partial remission (PR) was defined as > 75% reduction of the serum 
monoclonal Ig, at least 90% reduction in 24-hour urinary light chain excretion, no increase in size or number 
of osteolytic lesions or increase in marrow plasma cells. Patients with less than a PR after induction or 
autografting were considered refractory; the disease was considered stable if neither CR or PR was 
observed after allografting. Progressive disease was defined as a > 25% increase in serum monoclonal Ig or 
urine light chains in patients with refractory or stable disease; relapse as the reappearance of marrow 
plasma cells, serum monoclonal Igs, urinary light chains or new bone lesions in patients in CR, or a 25% 
increase in any disease marker for patients in PR. 
Statistical analysis 
 Primary endpoints were overall survival (OS) and event-free survival (EFS) from diagnosis by the intention-
to-treat principle. Secondary endpoints included OS and EFS, disease response and TRM in patients who 
completed the assigned procedures. Survival was calculated by the Kaplan-Meier method from diagnosis 
until death from any cause for OS, and from diagnosis until progression, relapse, or death from any cause 
for EFS. OS was also evaluated from the start of salvage therapy after the allograft or the second high-dose 
autograft. Incidences of TRM, acute GVHD, and chronic limited or extensive GVHD, of being on 
immunosuppression (IS) after developing chronic GVHD, and of dying while on IS were calculated by the 
cumulative incidence method by Gooley et al.13 Death without chronic GVHD was considered a competing 
risk for chronic GVHD; getting off of IS was considered a competing risk for dying while on IS. Dying while 
on IS was considered a competing risk for getting off of IS. Deaths because of nonrelapse causes, except for 
nonhematologic malignancies, were regarded as TRM. Proportions between groups were compared with 
the Fisher exact test. Differences in OS and EFS were estimated with the Cox proportional hazards model. 
All P values from regression models were derived from the log-rank test. After the allograft or the second 
autograft, the probability that a patient was alive in the original CR and PR, or in a subsequent remission 
after salvage treatment, was estimated via an extension of the method described by Couper and Pepe, 
allowing for multiple transitions between remission and relapse states.14 Multivariate models included 
presence or absence of an HLA-identical, sibling age, sex, myeloma protein isotype, Durie & Salmon stage, 
disease response at the first autograft. SAS 8.2 statistical software (SAS Institute) and R 2.1.0, package 
“cmprsk” were used. 
Results 
Treatment assignment 
 
Patient characteristics are reported in Table 1. Prognostic factors were evenly distributed in all 
subgroups.12 Of the 162 HLA-typed patients, 80 had at least 1 potential HLA-identical donor and 60 of 
them were enrolled in a nonmyeloablative allograft program. Fifteen (18%) who refused because of 
concerns about TRM and 5 (6%) who had ineligible donors were included in the intention-to-treat analysis. 
Fifty-eight (97%) of the 60 completed their assigned treatment. Of the 82 without donors, 59 were enrolled 
in the double high-dose melphalan autograft and 46 (78%) completed the planned treatment. The 
remaining patients were either ineligible for chemotherapy or received reduced doses of melphalan. 
 Long-term transplant-related toxicity and mortality 
Nonmyeloablative allografts. 
 
Grade II-IV acute GVHD developed in 40% (23 of 58) of the patients.12 Of 55 patients, limited and extensive 
chronic GVHD developed in 9 (16%) and in 32 at a median of 199 (range 100-441) and 199 (range 84-1192) 
days. 
 
After a median follow-up of 7.3 (range 5.4-10.4+) years from diagnosis and 6.5 (range 4.2-9.4+) years from 
the nonmyeloablative allograft, 24 of 58 (41%) patients died: 13 (22%) from disease progression, 9 (16%) 
from TRM and 2 (3%) from lung cancer. TRM was mainly because of complications associated with acute 
GVHD and chronic GVHD. Four patients in CR died of TRM. 
 
High-dose melphalan autografts. 
 
Overall, 13 (22%) of the 59 patients did not complete the assigned treatment because of disease 
progression (no. 4), disease-related renal failure (no. 3), TRM (no. 1), consent withdrawal (no. 3), and poor 
PBSC mobilization (no. 2). 
 
After a median follow-up of 7.4 (range 5.6-10.7+) years from diagnosis and 6.2 (range 4.7-9.1+) years from 
the second autograft, 30 (65%) of the 46 patients died: 26 (56%) from disease progression, 1 (2%) from 
TRM (invasive aspergillosis), 1 (2%) from gall bladder cancer, and 2 (4%) of complications during salvage 
treatments. 
Disease response 
Nonmyeloablative allografts. 
 
At the time of allografting, 8 (14%) of the 58 patients were in CR and 36 (62%) in PR giving an overall 
response (CR + PR) of 76%. Thirty-two (55%) of the 58 achieved CR at a median time of 5 months after the 
nonmyeloablative allograft (range 0-35) and 18 (31%) PR, for an overall response rate of 86%. One 
additional patient, after obtaining an initial PR achieved CR after subsequent salvage therapy. The 
achievement of CR was not associated with the development of chronic GVHD (P = 1). Twelve (37%) of the 
32 patients in CR and 9 (50%) of the 18 in PR subsequently relapsed. 
 
High-dose melphalan autografts. 
 
At the time of the second autograft, 4 (9%) of the 46 patients were in CR and 31 (67%) in PR for an overall 
“chemosensitive disease” of 76% (35/46). After the second autograft, 12 (26%) patients entered CR and 30 
(65%) PR for an overall response rate of 91%. Overall, 35 (83%) patients relapsed from a previous CR or PR. 
 
Overall response rates (CR + PR) at the time and after the nonmyeloablative allograft and at the time and 
after the second autograft did not differ between the 2 cohorts (P = 1 and P = 0.54, respectively). However, 
the CR rate was significantly higher after the nonmyeloablative allograft than after the second autograft (P 
= .0026). 
Salvage therapy 
Nonmyeloablative allografts. 
 
Overall, 30 of the 58 patients were treated for disease relapse/progression after the nonmyeloablative 
allograft. First-line salvage therapy consisted of bortezomib- or thalidomide-containing regimens in 19, 
standard chemotherapy and/or radiotherapy in 7, and 1 patient was treated with a rapid taper of the IS. 
Furthermore, 9 of these patients also received DLI. Three patients received DLI alone, and of them only 1 
achieved a transient response. 
 
After 1-3 lines of salvage therapy, 22 of 30 (73%) had a response, including 5 CR and 17 PR; 12 (54%) of 22 
experienced a second relapse and 3 (25%) of 12 still showed responsive disease. 
 
High-dose melphalan autografts. 
 
Thirty-nine patients experienced relapse/progression after the second autograft. First-line salvage therapy 
consisted of bortezomib- (no. 8) or thalidomide/lenalidomide-containing regimens (no. 19) in 27 patients, 
and standard chemotherapy and/or radiotherapy in 10. One patient had not been treated and another 
patient was lost to follow-up. Overall, 4 (11%) of the treated patients obtained a CR and 16 (43%) a PR for 
an overall response rate of 54%. Fourteen (70%) of these 20 patients experienced a second relapse. 
Long-term clinical outcomes 
 
At a median follow-up of 7.1 (range 2.5-10.7+) years, median OS of all 245 patients was 5.2 years; however, 
by intention-to-treat analysis, median OS and EFS were significantly longer in patients with HLA-identical 
siblings compared with those without: not reached vs 4.25 years (hazard ratio [HR] 0.51, confidence 
interval [CI] 95% 0.34-0.76, P = .001) and 2.8 vs 2.4 years (HR 0.62, CI 95% 0.44-0.87, P = .005; Figure 2A-B). 
By multivariate analysis, independent of age, sex, myeloma protein isotype, Durie & Salmon stage, and 
disease status at the first autograft, the presence of an HLA-identical sibling and, therefore, the possibility 
of an allograft, was significantly associated with longer OS (HR 0.5, CI 95% 0.3-0.8, P = .001) and EFS (HR 
0.63, CI 95% 0.4-0.9, P = .01; Table 2). Disease status at the first autograft and myeloma protein isotype 
showed a significant impact on EFS. 
  
At a median follow-up of 7.3 (range 5.4-10.7+) years, median OS was not reached in the 58 patients who 
received a nonmyeloablative allograft and 5.3 years (range 0.9-10.7+) in the 46 who received a second high-
dose melphalan autograft (HR 0.55, CI 95% 0.32-0.94, P = .02), whereas EFS was 39 months and 33 months 
(HR 0.62, CI 95% 0.40-0.96, P = .02), respectively (Figure 2C-D). By multivariate analysis, patients who 
received the nonmyeloablative allograft showed significantly improved OS (HR 0.56, CI 95% 0.3-1.0, P = .04) 
and EFS (HR 0.60, 95% CI 0.4-0.9, P = .02) compared with those who received a second high-dose melphalan 
(Table 2). 
 
The probability of a patient being alive in the original or in a subsequent CR or PR after salvage treatments 
after the nonmyeloablative allograft and the second autograft is illustrated in Figure 3. At a median follow-
up of 3.9 years from relapse, OS was not reached and 1.7 years in patients who had relapsed after the 
nonmyeloablative allograft and the second high-dose melphalan (HR 0.44, CI 95% 0.24-0.82, P = .01; Figure 
3). 
 
 
 
Long-term immunosuppression 
 
Forty-one (74%) of 55 patients developed limited or extensive chronic GVHD. At 3 years from the allograft, 
34 were alive, 15 were on IS, and 19 were not. At the time of this report, 31 had reached a follow-up of at 
least 5 years: 5 died while on IS whereas 23 were alive off IS and only 3 were still on IS (Figure 4). Overall, 
19 (66%) of 29 discontinued IS because of resolution of chronic GVHD while 10 (34%) of 29 underwent a 
rapid IS taper after relapse. 
 
Discussion 
 
Allografting in myeloma has hotly been debated since its clinical introduction.15 Lower relapses following 
allografts rather than autografts were already reported in the late 1990s, though this did not translate into 
better OS given the high TRM.16 Recently, reduced-intensity or truly nonmyeloablative conditionings have 
been investigated.10,11,17,18 
 
Before the era of “new drugs,” whether nonmyeloablative allografting could improve OS and EFS compared 
with autografting was a matter of debate.19 In our study, treatment assignment was based only on the 
presence or absence of HLA-identical siblings. Neither induction treatments with “new drugs” nor currently 
used maintenance/consolidation therapies were included in the study. Previously reported results were 
encouraging.12 Here, we have extended follow-up to a median of 7 years. 
 
Median OS of our entire study population was 5.2 years, consistent with the expected OS for patients 
diagnosed during the study period.20 At a median follow-up of 7.1 year, both OS and EFS were significantly 
longer in patients with HLA-identical siblings than those without. Median OS was not reached in the 
allograft patients while EFS was 39 months. Both OS and EFS remained significantly longer compared with 
those patients treated with 2 autografts who showed OS of 5.3 years and EFS of 33 months. Cavo et al 
reported median EFS of 23 and 35 months after single and double autologous transplantation, 
respectively.21 However, it is important to point out that more recent reports on the use of maintenance 
therapy after autografting have shown remarkable improvements. McCarthy et al reported an estimated 
median time to progression of 42 months in patients treated with lenalidomide after a single autograft, 
while Attal et al reported a progression-free survival of 42 months from the time of randomization in the 
arm with lenalidomide as maintenance compared with 24 months in the placebo arm.22,23 These trials 
may define a new standard of treatment which includes maintenance after autografting. No definitive data 
are currently available on the use of new drugs after allografting. 
 
Other studies comparing allografting with autografting have been reported.24–29 All included an autograft 
before a reduced-intensity allograft. The first published study by the Intergroupe Farmaphene du Myelome 
(IFM) enrolled high-risk patients. A recent update showed no significant differences in EFS and OS with a 
trend for poorer survival in the allograft patients.24 One study by the PETHEMA group randomized 25 
patients to receive the allograft and 85 a second autograft.25 All patients had failed to achieve at least 
near-CR after a first autograft. The median time for progression free survival and OS had not been reached 
in the allograft cohort, whereas they were 31 months and 58 months in the autograft group, respectively. 
 
Three other studies used the “Seattle regimen” with low-dose TBI after a cytoreductive autograft.26–29 In 
the HOVON study, the control cohort was treated with one autograft followed by maintenance with 
thalidomide. An interim analysis showed no significant differences in EFS and OS between the 2 cohorts of 
124 patients each: 39% vs 34% and 56% vs 63% at 4 years in the allograft group and the autograft-
thalidomide group, respectively.26 The recently closed EBMT study enrolled 107 patients with an HLA-
identical sibling and 251 without from 26 European Centers. Eighty-eight and 104 patients completed the 
assigned treatments, respectively.27 By intention-to-treat analysis and in those patients who completed 
the assigned treatment, the risk of relapse was significantly lower in the allograft cohort. Despite a 
significantly higher TRM, 13% versus 5%, a trend for better OS was seen in the allograft cohort in both poor 
and good prognosis subgroups. Clinical findings of a large US multicenter trial from the Blood and Marrow 
Transplant Clinical Trials Network were recently reported.28,29 A total of 710 patients were randomized at 
43 US transplant centers. Induction treatments were not standardized and patients could be enrolled after 
HLA typing between 3 and 9 months from the start of systemic induction therapy. Patients were defined as 
standard or high risk in the light of high β-2-microglobulin levels and chromosomal abnormalities by 
standard cytogenetics. Both intention-to-treat and as-treated analyses showed equivalent 3-year 
progression-free survival and OS in standard-risk patients whereas there were trends in late progression-
free survival and time to progression in high-risk patients who underwent allografting.28,29 
 
All these studies used a Mendelian randomization as a surrogate for a more formal randomization.30 
However, given substantial differences in the study inclusion criteria and treatment schemas, results are 
inevitably conflicting. 
 
We reported the clinical outcomes of the entire young population of patients consecutively diagnosed at 
our centers, regardless of the treatment protocol. This is rarely reported in phase 2-3 studies preventing 
the readers from knowing the proportion of patients actually eligible and eventually enrolled in a given 
protocol. We initially defined 2 patient cohorts with and without potential donors. This did not imply that 
all patients were eligible for investigational phase 2-3 studies either because of comorbidities, patient will, 
or donor eligibility. Of the patients enrolled in the nonmyeloablative allograft arm and in the tandem 
autograft arm, 96% and 78%, respectively, completed the assigned treatment. The inclusion of all eligible 
patients in the allograft cohort, regardless of disease stage and prognostic factors, gave a good chance to 
capture the subset who most benefited from graft-vs-myeloma that resulted in long-term disease-free 
survival. Unfortunately, our study was not designed to detect any myeloma-specific marker that could 
possibly predict plasma cell sensitivity to graft-vs-myeloma. 
 
Chronic GVHD may be cause of long-term morbidity and poor quality of life. However, IS discontinuation 
because of its resolution greatly improves quality of life and may be used as a surrogate of the achievement 
of immunotolerance. Importantly, most of our surviving patients, at 5 years after the allograft, had 
discontinued IS because of continued resolution of GVHD. 
 
Molecular remissions, prerequisite for cure, have more frequently been observed after myeloablative 
allografting rather than autografting with/without consolidation therapy.31–33 The cumulative risk of 
relapse at 5 years was 0% for patients with durable PCR negativity after the allograft. We previously 
reported molecular remission after low-dose TBI allografting.34 Some remissions were reached months 
after transplantation suggesting a gradual graft-versus-myeloma effect that may be less effective in bulky 
and aggressive diseases. A currently in-progress large retrospective study on molecular responses will help 
define whether the intensity of the conditioning or graft versus myeloma is more important to obtain 
molecular remissions. 
 
After the introduction of “new drugs,” allografting has become a far less attractive option because of its 
toxicity. The role of allografting, however, may prospectively be evaluated in selected high-risk patients 
where life expectancy remains very poor despite the use of bortezomib and lenalidomide.35 Although 
genetic abnormalities such as del(17p) were shown to have a negative prognostic factor in a retrospective 
analysis on patients transplanted from both related and unrelated donors, the combination of allografting 
with “new drugs” has not yet been thoroughly explored.36 The efficacy of “new drugs” in patients relapsed 
after allografting has already been reported.37,38 Interestingly, we observed higher response rates to 
salvage therapies in the allograft patients and OS from relapse was significantly longer after the allograft 
than the second autograft (P = .01). Although not part of a prospective trial, this finding may partly be 
explained by the hypotheses that the high percentage of donor T cells, usually seen at relapse after a 
nonmyeloablative allograft, may synergize with immunomodulatory drugs and help restore graft versus 
myeloma or that donor cells may favor the antimyeloma effects of these drugs in the marrow milieu. 
 
In summary, a subset of patients may have been cured with an allograft given the persistent disease free 
status extending up to longer than 10 years. However, given the risk of transplantation-related toxicity and 
the recent remarkable advancements in newly diagnosed myeloma patients, the combination of 
allografting with new drugs should most preferably be explored in high-risk patients, where life expectancy 
is poor, in prospective clinical trials. 
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